Australia's women's health research landscape: assets, gaps, and translation potential

Australia punches above its weight in women's health research. Programs at Sydney, Melbourne, Monash, UNSW, and Queensland produce internationally cited work in endometriosis, fertility, maternal-fetal medicine, and ovarian biology. UNSW's Endometriosis Centre has contributed to studies estimating that 1 in 9 Australian women live with the condition. Monash University's Ritchie Centre is a global leader in perinatal research, and the Robinson Research Institute in Adelaide drives nationally significant work in reproductive health. The 43.5% R&D Tax Incentive makes early-stage evidence generation more capital-efficient than comparable markets in the US or Europe.

Yet the pipeline from research to investable ventures remains thin. Only 0.6% of Australian venture capital went to women's health between 2015 and 2022, according to data compiled by FemTech Analytics. University technology transfer offices are stretched across all disciplines, with limited bandwidth for the kind of specialist translation support that women's health assets require — regulatory pathway mapping, endpoint design for heterogeneous conditions, and reimbursement modelling in Australian and international markets.

The clinical trial infrastructure is strong but underutilised for women's health translation. The NHMRC Clinical Trials Centre, the Perinatal Trials Unit, and networks like the Australasian Diabetes in Pregnancy Society have global credibility. These are assets that a specialist translation platform can connect to ventures at the right stage — not after a trial has already been designed around the wrong endpoints.

The result is a structural paradox: strong science, capable institutions, favourable tax settings, established trial networks — and a persistent gap where ventures stall between proof-of-concept and the evidence package needed to attract institutional capital or industry partners. That gap is addressable, but not by generic support.